OncoCyte Corp
NASDAQ:OCX

Watchlist Manager

OncoCyte Corp

NASDAQ:OCX

Watchlist

Dividends

Price: 2.21 USD 0.91%

Market Cap: 37.2m USD

Have any thoughts about
OncoCyte Corp?

Write Note

Write Note Create Alert Ask AI

Add Note Why Create Notes?

Capture your thoughts

Note Buy Sell Hold Pass

US	Johnson & Johnson NYSE:JNJ	Pharmaceuticals
US	Berkshire Hathaway Inc NYSE:BRK.A	Financial Services
US	Bank of America Corp NYSE:BAC	Banking
US	Mastercard Inc NYSE:MA	Technology
US	UnitedHealth Group Inc NYSE:UNH	Health Care
US	Exxon Mobil Corp NYSE:XOM	Energy
US	Pfizer Inc NYSE:PFE	Pharmaceuticals
US	Palantir Technologies Inc NYSE:PLTR	Technology
US	Nike Inc NYSE:NKE	Textiles, Apparel & Luxury Goods
US	Visa Inc NYSE:V	Technology
CN	Alibaba Group Holding Ltd NYSE:BABA	Retail
US	3M Co NYSE:MMM	Industrial Conglomerates
US	JPMorgan Chase & Co NYSE:JPM	Banking
US	Coca-Cola Co NYSE:KO	Beverages
US	Walmart Inc NYSE:WMT	Retail
US	Verizon Communications Inc NYSE:VZ	Telecommunication

Add Price Alert

Price Target:

Last Price: 2.21 USD

We'll email you a reminder when the closing price reaches USD.

If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.

Peter Lynch

Track and Analyze Performance

Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.

Continuous Learning and Adaptation

Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.

Boost Decision Confidence

With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.

Why create notes?

Back

Delete Note

Do you really want to delete this note?
This action cannot be undone.

Remove price alert for reaching

Delete

Cancel

OCX Alert

OncoCyte Corp

2.21

+0.02 (+0.91%)

52 Week Range	2.19 3.6
Price Target

We'll email you a reminder when the closing price reaches USD.

Save Alert

Choose the stock you wish to monitor with a price alert.

	Johnson & Johnson NYSE:JNJ	US
	Berkshire Hathaway Inc NYSE:BRK.A	US
	Bank of America Corp NYSE:BAC	US
	Mastercard Inc NYSE:MA	US
	UnitedHealth Group Inc NYSE:UNH	US
	Exxon Mobil Corp NYSE:XOM	US
	Pfizer Inc NYSE:PFE	US
	Palantir Technologies Inc NYSE:PLTR	US
	Nike Inc NYSE:NKE	US
	Visa Inc NYSE:V	US
	Alibaba Group Holding Ltd NYSE:BABA	CN
	3M Co NYSE:MMM	US
	JPMorgan Chase & Co NYSE:JPM	US
	Coca-Cola Co NYSE:KO	US
	Walmart Inc NYSE:WMT	US
	Verizon Communications Inc NYSE:VZ	US

Delete Alert

This alert will be permanently deleted.

Remove note

Delete

Cancel

Ask me anything about

OncoCyte Corp

What unique competitive advantages
does OncoCyte Corp hold over its rivals?

What risks and challenges
does OncoCyte Corp face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Provide an overview of the primary business activities
of OncoCyte Corp.

What unique competitive advantages
does OncoCyte Corp hold over its rivals?

What risks and challenges
does OncoCyte Corp face in the near future?

Has there been any significant insider trading activity
in OncoCyte Corp recently?

Summarize the latest earnings call
of OncoCyte Corp.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for OncoCyte Corp.

Provide P/S
for OncoCyte Corp.

Provide P/E
for OncoCyte Corp.

Provide P/OCF
for OncoCyte Corp.

Provide P/FCFE
for OncoCyte Corp.

Provide P/B
for OncoCyte Corp.

Provide EV/S
for OncoCyte Corp.

Provide EV/GP
for OncoCyte Corp.

Provide EV/EBITDA
for OncoCyte Corp.

Provide EV/EBIT
for OncoCyte Corp.

Provide EV/OCF
for OncoCyte Corp.

Provide EV/FCFF
for OncoCyte Corp.

Provide EV/IC
for OncoCyte Corp.

Show me price targets
for OncoCyte Corp made by professional analysts.

What are the Revenue projections
for OncoCyte Corp?

How accurate were the past Revenue estimates
for OncoCyte Corp?

What are the Net Income projections
for OncoCyte Corp?

How accurate were the past Net Income estimates
for OncoCyte Corp?

What are the EPS projections
for OncoCyte Corp?

How accurate were the past EPS estimates
for OncoCyte Corp?

What are the EBIT projections
for OncoCyte Corp?

How accurate were the past EBIT estimates
for OncoCyte Corp?

Compare the revenue forecasts
for OncoCyte Corp with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of OncoCyte Corp and its key competitors using the latest financial data.

Compare historical revenue growth rates
of OncoCyte Corp against its competitors.

Analyze the profit margins
(gross, operating, and net) of OncoCyte Corp compared to its peers.

Compare the P/E ratios
of OncoCyte Corp against its peers.

Discuss the investment returns and shareholder value creation
comparing OncoCyte Corp with its peers.

Analyze the financial leverage
of OncoCyte Corp compared to its main competitors.

Show all profitability ratios
for OncoCyte Corp.

Provide ROE
for OncoCyte Corp.

Provide ROA
for OncoCyte Corp.

Provide ROIC
for OncoCyte Corp.

Provide ROCE
for OncoCyte Corp.

Provide Gross Margin
for OncoCyte Corp.

Provide Operating Margin
for OncoCyte Corp.

Provide Net Margin
for OncoCyte Corp.

Provide FCF Margin
for OncoCyte Corp.

Show all solvency ratios
for OncoCyte Corp.

Provide D/E Ratio
for OncoCyte Corp.

Provide D/A Ratio
for OncoCyte Corp.

Provide Interest Coverage Ratio
for OncoCyte Corp.

Provide Altman Z-Score Ratio
for OncoCyte Corp.

Provide Quick Ratio
for OncoCyte Corp.

Provide Current Ratio
for OncoCyte Corp.

Provide Cash Ratio
for OncoCyte Corp.

What is the historical Revenue growth
over the last 5 years for OncoCyte Corp?

What is the historical Net Income growth
over the last 5 years for OncoCyte Corp?

What is the current Free Cash Flow
of OncoCyte Corp?

Discuss the annual earnings per share (EPS)
trend over the past five years for OncoCyte Corp.

EV/EBITDA
Enterprise Value to EBITDA

-0.8

Current

-1.2

Median

4.2

Industry

Higher than median

Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA

-0.8

Enterprise Value

34.2m USD

EBITDA

-42.3m USD

All Countries

Forward Multiples

			Market Cap	EV/EBITDA
US		OncoCyte Corp NASDAQ:OCX	36.9m USD	-0.8
FR		Pharnext SCA OTC:PNEXF	6T USD	-219 476
US		Abbvie Inc NYSE:ABBV	310.3B USD	15.2
US		Amgen Inc NASDAQ:AMGN	141.6B USD	16
US		Gilead Sciences Inc NASDAQ:GILD	115.3B USD	10.2
US		Vertex Pharmaceuticals Inc NASDAQ:VRTX	102.4B USD	21
US	E	Epizyme Inc F:EPE	94.1B EUR	-514.8
AU		CSL Ltd ASX:CSL	134.4B AUD	19.7
US		Regeneron Pharmaceuticals Inc NASDAQ:REGN	77.3B USD	15.1
US	S	Seagen Inc F:SGT	39.3B EUR	-58.8
NL		argenx SE XBRU:ARGX	35.8B EUR	-108.8

				EBITDA Growth	EV/EBITDA to Growth
US		OncoCyte Corp NASDAQ:OCX	Average EV/EBITDA: 16.2 Negative Multiple: -0.8	N/A	N/A
FR		Pharnext SCA OTC:PNEXF	Negative Multiple: -219 476	N/A	N/A
US		Abbvie Inc NYSE:ABBV	15.2	29%	0.5
US		Amgen Inc NASDAQ:AMGN	16	62%	0.3
US		Gilead Sciences Inc NASDAQ:GILD	10.2	16%	0.6
US		Vertex Pharmaceuticals Inc NASDAQ:VRTX	21	43%	0.5
US	E	Epizyme Inc F:EPE	Negative Multiple: -514.8	N/A	N/A
AU		CSL Ltd ASX:CSL	19.7	42%	0.5
US		Regeneron Pharmaceuticals Inc NASDAQ:REGN	15.1	35%	0.4
US	S	Seagen Inc F:SGT	Negative Multiple: -58.8	N/A	N/A
NL		argenx SE XBRU:ARGX	Negative Multiple: -108.8	N/A	N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward

EV/EBITDA

-4.7

2-Years Forward

EV/EBITDA

-1.6

3-Years Forward

EV/EBITDA

-1.9

	Franklin Covey Co NYSE:FC	36.1 USD -0.85%
	Mohawk Industries Inc NYSE:MHK	118.07 USD -0.91%
	Ardmore Shipping Corp NYSE:ASC	11.49 USD 1.59%
	ASGN Inc NYSE:ASGN	83.9 USD 0.04%
	Skyworks Solutions Inc NASDAQ:SWKS	89.91 USD 1.31%
	Weatherford International PLC NASDAQ:WFRD	67.1 USD -2.13%

	Johnson & Johnson NYSE:JNJ	143.99 USD -0.33%
	Bank of America Corp NYSE:BAC	43.89 USD -0.63%
	Mastercard Inc NYSE:MA	526.71 USD -0.26%
	Salesforce Inc NYSE:CRM	340.04 USD -1.05%
	Abbvie Inc NYSE:ABBV	175.28 USD -0.17%
	Home Depot Inc NYSE:HD	388.5 USD -1.04%

	Arista Networks Inc NYSE:ANET	112.4562 USD -0.31%
	Visa Inc NYSE:V	315.785 USD -0.61%
	Texas Pacific Land Corp NYSE:TPL	1 140 USD 0.61%
	KLA Corp NASDAQ:KLAC	633 USD 0.58%
	Manhattan Associates Inc NASDAQ:MANH	280.26 USD -0.81%
	Pinduoduo Inc NASDAQ:PDD	100.09 USD 0.58%

	Salesforce Inc NYSE:CRM	340.04 USD -1.05%
	Accenture PLC NYSE:ACN	361.25 USD -1.4%
	ServiceNow Inc NYSE:NOW	1 086.7 USD -0.42%
	EOG Resources Inc NYSE:EOG	118.65 USD -0.33%
	Copart Inc NASDAQ:CPRT	58.06 USD -0.27%
	Applied Materials Inc NASDAQ:AMAT	166.015 USD 1.48%

OncoCyte Corp
NASDAQ:OCX

EV/EBITDA
Enterprise Value to EBITDA

EV/EBITDA Forward Multiples

See Also

Company

Help

Tools

Stocks

OncoCyte Corp NASDAQ:OCX

EV/EBITDA Enterprise Value to EBITDA

EV/EBITDA Forward Multiples

See Also

Company

Help

Tools

Stocks

OncoCyte Corp
NASDAQ:OCX

EV/EBITDA
Enterprise Value to EBITDA